MANNHEIM, Germany, August 10 /PRNewswire/ -- MIDAS Research has published
a research report on the nano-medical technology company Biophan
Technologies, Inc. (OTC BB: BIPH, Frankfurt: BTN) with a 12 month target
price per share of USD 4.20 and a buy recommendation. A copy of the report is
available in both German and English at www.midasresearch.de .
Biophan Technologies, Inc. develops, acquires, and markets technology
solutions (patents) that solve significant problems arising when patients
with implanted devices require magnetic resonance imaging (MRI) diagnostics.
Currently, patients with implanted devices are denied the highly effective
MRI procedure, as MRI can adversely affect the functioning of implanted
In the opinion of MIDAS Research analyst Curtis Schneekloth, CFA, Biophan
correctly belongs to the most discussed nanotech equities both in the USA and
in Germany. In contrast to other nanotech stocks, the share price potential
is already backed up to a large extent by a recent business agreement with
Boston Scientific Corp., a market leader in coronary vessel implants (stents).
MIDAS Research is an independent stock research company with a global
focus on emerging industries and undervalued small caps particularly in the
field of life sciences. Recent reports have successfully highlighted stocks
like MorphoSys (GER), Mologen (GER), DuraVest (USA) or Dermisonics (USA).
For further contacts:
SOURCE MIDAS Research GmbH